nivo/ipi vs. chemo: key results from checkmate 227 (bmic-034)
Published 6 years ago • 388 plays • Length 13:07Download video MP4
Download video MP3
Similar videos
-
8:57
nivo/ipi rx of choice for adv. nsclc, pd-l1 under 1%, high tmb? new checkmate 227 data (bmic-040)
-
9:40
are tmb and nivolumab/ipilimumab ready for clinical use? insights from checkmate 227 (bmic-035)
-
9:14
results from checkmate-227 : immune combination reaches pfs endpoint
-
2:33
checkmate 227: chemo-free nsclc treatment
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
-
8:58
what does the checkmate-331 trial of nivolumab vs. chemo for relapsed sclc tell us? (bmic-072)
-
17:08
three-year update from the checkmate 227 clinical trial for advanced nsclc
-
6:31
checkmate 649 biomarker analyses of nivo ipi vs chemo for patients with gc/gejc/eac
-
6:07
interpreting the results of checkmate-227 in nsclc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
9:40
asco 2018 - checkmate 227 - combinations of nivolumab and ipilimumab, or nivolumab and and chemo
-
5:31
checkmate-227: nivolumab ipilimumab in mnsclc
-
4:32
updated data in stage iv nsclc: checkmate-227
-
7:23
surgical outcomes from checkmate 816: nivo plus chemo vs chemo alone as neoadjuvant treatment fo...
-
2:26
checkmate 227 update
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
1:49
checkmate 901: hrqol findings of nivolumab and gemcitabine-cisplatin in uc
-
3:09
#esmo21 highlights on nivo ipi vs extreme in 1st-line high-risk scchn: the checkmate 651 study